Cargando…
Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870292/ https://www.ncbi.nlm.nih.gov/pubmed/24391651 http://dx.doi.org/10.3389/fimmu.2013.00481 |
_version_ | 1782296688028811264 |
---|---|
author | Mentlik James, Ashley Cohen, Adam D. Campbell, Kerry S. |
author_facet | Mentlik James, Ashley Cohen, Adam D. Campbell, Kerry S. |
author_sort | Mentlik James, Ashley |
collection | PubMed |
description | Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by directing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous therapeutic mAb have been developed that target distinct cancer-specific cell markers and may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity. These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can potentiate NK cell cytotoxicity through other mechanisms are being used in combination with therapeutic mAb. In this review, we examine the mechanisms employed by several promising agents used in combination therapies that enhance natural or Ab-dependent cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple myeloma. |
format | Online Article Text |
id | pubmed-3870292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-38702922014-01-03 Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells Mentlik James, Ashley Cohen, Adam D. Campbell, Kerry S. Front Immunol Immunology Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by directing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous therapeutic mAb have been developed that target distinct cancer-specific cell markers and may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity. These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can potentiate NK cell cytotoxicity through other mechanisms are being used in combination with therapeutic mAb. In this review, we examine the mechanisms employed by several promising agents used in combination therapies that enhance natural or Ab-dependent cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple myeloma. Frontiers Media S.A. 2013-12-23 /pmc/articles/PMC3870292/ /pubmed/24391651 http://dx.doi.org/10.3389/fimmu.2013.00481 Text en Copyright © 2013 Mentlik James, Cohen and Campbell. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Mentlik James, Ashley Cohen, Adam D. Campbell, Kerry S. Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title | Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title_full | Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title_fullStr | Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title_full_unstemmed | Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title_short | Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells |
title_sort | combination immune therapies to enhance anti-tumor responses by nk cells |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870292/ https://www.ncbi.nlm.nih.gov/pubmed/24391651 http://dx.doi.org/10.3389/fimmu.2013.00481 |
work_keys_str_mv | AT mentlikjamesashley combinationimmunetherapiestoenhanceantitumorresponsesbynkcells AT cohenadamd combinationimmunetherapiestoenhanceantitumorresponsesbynkcells AT campbellkerrys combinationimmunetherapiestoenhanceantitumorresponsesbynkcells |